Our Mission

To transform the lives of patients living with autoimmune diseases.

Our Pipeline

Rapidly advancing a deep portfolio of innovative autoimmune therapeutics that continues to expand through our successful business development strategy.

Latest News

September 5, 2023

Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb

August 1, 2023

Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology

long-arrow-right-regularfacebook-brandsfacebook-f-brandsinstagram-brandslinkedin-brandslinkedin-in-brandssubmit-arrowtwitter-brandstwitter-square-brandsyoutube-brands